Who is sponsoring NCT07117942?

NCT07117942 is sponsored by Helwan University.

What condition does NCT07117942 study?

NCT07117942 studies Diabetic Neuropathy.

What drugs are being tested in NCT07117942?

Interventions: Fermented Deglycyrrhizinated Licorice (FDGL).

What is the status of NCT07117942?

NCT07117942 is currently COMPLETED.

Last reviewed 2025-08-17 · How we verify

FDGL Dose-Finding Study for Diabetic Neuropathy

NCT07117942 PHASE2 COMPLETED

This study investigates the optimal dose of fermented deglycyrrhizinated licorice (FDGL) that maximizes both safety and efficacy in managing diabetic neuropathy complications in adults. The study is a single-center, double-blind, parallel, placebo-controlled randomized clinical trial where patients with diabetic neuropathy are randomized to receive placebo, 400 mg, 800 mg, 1000 mg, or 1200 mg daily doses of FDGL for three months. The primary objective is to determine the percentage improvement of diabetic neuropathy presentations and pain scores at three months relative to baseline.

Details

Lead sponsor	Helwan University
Phase	PHASE2
Status	COMPLETED
Enrolment	485
Start date	Wed Feb 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Diabetic Neuropathy

Interventions

Fermented Deglycyrrhizinated Licorice (FDGL)

Countries

Egypt